(o-Chlorophenylsulfonyl)carbamic acid | 138199-54-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (o-Chlorophenylsulfonyl)carbamic acid
• 英文别名: (2-Chlorobenzene-1-sulfonyl)carbamic acid；(2-chlorophenyl)sulfonylcarbamic acid
• CAS: 138199-54-9
• 化学式: C₇H₆ClNO₄S
• 分子量: 235.648
• InChiKey: FULSIHOOFUQXTB-UHFFFAOYSA-N

物化性质

• 密度：
  1.607±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  91.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (o-Chlorophenylsulfonyl)carbamic acid 在 磷酸 作用下， 以 various solvent(s) 为溶剂， 生成 二氧化碳 、 邻氯苯磺酰胺
  参考文献：
  名称：

  Kinetics and hydrolysis mechanism of chlorsulfuron and metsulfuron-methyl

  摘要：

  AbstractIn acidic media, hydrolysis of chlorsulfuron and metsulfuron‐methyl occurs via two consecutive reactions which were followed by ultraviolet spectrophotometry. For these two reactions, the pseudo‐first‐order rate constants increase proportionally to the concentration of hydronium ion in the more acidic media and to the square of this concentration at higher pH values.A kinetic study by HPLC shows that the first reaction leads to the formation of 4‐methoxy‐6‐methyl‐1,3,5‐triazin‐2‐amine and (o‐chlorophenylsulfonyl) carbamic acid for chlorsulfuron or (o‐methoxycarbonylphenylsulfonyl) carbamic acid for metsulfuronmethyl. The second reaction is the conversion of these sulfonylcarbamic acids to sulfonamides and carbon dioxide. The complete lack of saccharin and of o‐sulfamoyl benzoic acid proves that the ester function of the methoxycarbonyl group is stable.The lack of general acid‐base catalysis and a solvent deuterium isotope effect less than unity are consistent with a rate‐determining cleavage of the protonated substrate.In the basic pH range (10–14) a single reaction occurs, the nucleophilic substitution of the methoxy group on the triazine by a hydroxide group.

  DOI：

  10.1002/ps.2780400112
• 作为产物：
  描述：

  氯磺隆 在 磷酸 作用下， 以 various solvent(s) 为溶剂， 生成 2-氨基-4-甲氧基-6-甲基-1,3,5-三嗪 、 (o-Chlorophenylsulfonyl)carbamic acid
  参考文献：
  名称：

  Kinetics and hydrolysis mechanism of chlorsulfuron and metsulfuron-methyl

  摘要：

  AbstractIn acidic media, hydrolysis of chlorsulfuron and metsulfuron‐methyl occurs via two consecutive reactions which were followed by ultraviolet spectrophotometry. For these two reactions, the pseudo‐first‐order rate constants increase proportionally to the concentration of hydronium ion in the more acidic media and to the square of this concentration at higher pH values.A kinetic study by HPLC shows that the first reaction leads to the formation of 4‐methoxy‐6‐methyl‐1,3,5‐triazin‐2‐amine and (o‐chlorophenylsulfonyl) carbamic acid for chlorsulfuron or (o‐methoxycarbonylphenylsulfonyl) carbamic acid for metsulfuronmethyl. The second reaction is the conversion of these sulfonylcarbamic acids to sulfonamides and carbon dioxide. The complete lack of saccharin and of o‐sulfamoyl benzoic acid proves that the ester function of the methoxycarbonyl group is stable.The lack of general acid‐base catalysis and a solvent deuterium isotope effect less than unity are consistent with a rate‐determining cleavage of the protonated substrate.In the basic pH range (10–14) a single reaction occurs, the nucleophilic substitution of the methoxy group on the triazine by a hydroxide group.

  DOI：

  10.1002/ps.2780400112

文献信息

• EP4 receptor inhibitors to treat rheumatoid arthritis
  申请人：——

  公开号：US20020077329A1

  公开（公告）日：2002-06-20

  The invention features a method of treating rheumatoid arthritis in a mammal comprising administering an agent that inhibits prostaglandin EP4 receptor (EP4) activity. Also featured is a method of identifying agents that selectively inhibit EP4 activity in vivo.

  该发明涉及一种治疗哺乳动物类风湿性关节炎的方法，包括给予一种抑制前列腺素EP4受体（EP4）活性的药物。还涉及一种识别在体内选择性抑制EP4活性的药物的方法。
• Imidazole compounds as anti-inflammatory and analgesic agents
  申请人：——

  公开号：US20030220372A1

  公开（公告）日：2003-11-27

  This invention provides a compound of the formula (I): 1 wherein: R 1 represents a hydrogen atom, an alkyl group, etc.; R 2 represents a hydrogen atom, a halogen atom, etc.; R 3 represents a hydrogen atom, an alkyl group, etc.; R 4 represents an aryl group, etc.; A represents an aryl 1 , etc; B represents an alkylene etc.; X represents NH, etc.; or a pharmaceutically acceptable ester of such compound, and pharmaceutically acceptable salts thereof. These compounds are useful for the treatment of medical conditions mediated by prostaglamndin such as pain, fever or inflammation, etc. This invention also provides a pharmaceutical composition comprising the above compound.

  这项发明提供了化合物的结构式(I)： 其中： R1代表氢原子、烷基等； R2代表氢原子、卤原子等； R3代表氢原子、烷基等； R4代表芳基等； A代表芳基1等； B代表烷基等； X代表NH等； 或者该化合物的药学上可接受的酯，及其药学上可接受的盐。这些化合物可用于治疗由前列腺素介导的医疗状况，如疼痛、发热或炎症等。该发明还提供了包含上述化合物的药物组合物。
• Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents
  申请人：——

  公开号：US20020107273A1

  公开（公告）日：2002-08-08

  This invention provides a compound of the formula (I): 1 or the pharmaceutically acceptable salts thereof, wherein Y 1 , Y 2 , Y 3 and Y 4 are independently selected from N, CH, etc.; R 1 is H, C 1-8 alkyl, etc.; Q 1 is a 5-12 membered monocyclic or bicyclic aromatic ring optionally containing up to 4 heteroatoms selected from O, N, and S, etc.; A is 5-6 membered monocyclic aromatic ring optionally containing up to 3 heteroatoms selected form O, N and S, etc.; B is C 1-6 alkylene optionally substituted with an oxo group, etc.; W is NH, O, etc.; R 2 is H, C 1-4 alkyl, etc.; Z is a 5-12 membered monocyclic or bicyclic aromatic ring optionally containing up to 3 heteroatoms selected form O, N and S, etc.; L is halo, C 1-4 alkyl, etc.; m is 0, 1 or 2; R 3 and R 4 are independently selected from H and C 1-4 alkyl; R 5 is H, C 1-4 alkyl; etc.; Q 2 is a 5-12 membered monocyclic or bicyclic aromatic ring or tricyclic ring optionally containing up to 3 heteroatoms selected from O, N and S, etc. These compounds are useful for the treatment of medical conditions mediated by prostaglamndin such as pain, fever or inflammation, etc. This invention also provides a pharmaceutical composition comprising the above compound.

  本发明提供了公式（I）的化合物或其药学上可接受的盐，其中Y1，Y2，Y3和Y4独立选择自N，CH等；R1是H，C1-8烷基等；Q1是5-12成员的单环或双环芳香环，可选含有高达4个杂原子，所选自O，N和S等；A是5-6成员的单环芳香环，可选含有高达3个杂原子，所选自O，N和S等；B是C1-6烷基，可选替代氧代基等；W是NH，O等；R2是H，C1-4烷基等；Z是5-12成员的单环或双环芳香环，可选含有高达3个杂原子，所选自O，N和S等；L是卤素，C1-4烷基等；m为0、1或2；R3和R4独立选择自H和C1-4烷基；R5是H，C1-4烷基等；Q2是5-12成员的单环或双环芳香环或三环环，可选含有高达3个杂原子，所选自O，N和S等。这些化合物可用于治疗由前列腺素介导的医疗状况，例如疼痛，发热或炎症等。本发明还提供了包含上述化合物的药物组合物。
• Use of EP4 Receptor Ligands in the Treatment of IL-6 Involved Diseases
  申请人：Shimojo Masato

  公开号：US20070066618A1

  公开（公告）日：2007-03-22

  Methods of treating IL-6 involved diseases with EP4 receptor ligands, including EP4 receptor antagonists. Assays to determine the effect of test compounds on PGE2-induced whole blood cells activation.

  使用EP4受体配体，包括EP4受体拮抗剂，治疗涉及IL-6的疾病的方法。测定试验化合物对PGE2诱导的全血细胞激活的影响的试验。
• Combinations Comprising Alpha-2-Delta Ligands and Ep4 Receptor Antagonists
  申请人：Audoly Laurent Pascal

  公开号：US20090036495A1

  公开（公告）日：2009-02-05

  The instant invention relates to a combination of an EP4-receptor antagonist and an alpha-2-delta ligand, and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof and their use in the treatment of pain, particularly inflammatory, neuropathic, visceral and nociceptive pain.

  本发明涉及一种EP4受体拮抗剂和α-2-δ配体的组合物，及其药学上可接受的盐、制药组合物及其在治疗疼痛，特别是炎症性、神经病理性、内脏性和伤害性疼痛中的用途。